Systematic identification of signaling pathways with potential to confer anticancer drug resistance

Colin A. Martz, Kathleen Ottina, Katherine R. Singleton, +16

Science Signaling

Drug TargetBreast OncologyCancer BiologyTamoxifen SensitivityTumor Biology +21

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

Suzanne E. Wardell, Matthew J. Ellis, Holly M. Alley, +12

Clinical Cancer Research

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

Suzanne E. Wardell, Erik R. Nelson, Christina Chao, +2

Endocrine Related Cancer

Breast Cancer MetastasisBreast OncologyPharmacotherapyPositive Breast CancerTumor Biology +16

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

John D. Norris, Stephanie J. Ellison, Jennifer G. Baker, +14

Journal of Clinical Investigation

<i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation

Grace R. Anderson, Suzanne E. Wardell, Lorin Crawford, +15

Science Translational Medicine

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

James P. Stice, Suzanne E. Wardell, John D. Norris, +11

Molecular Cancer Research

Lysine Auxotrophy Combined with Deletion of the SecA2 Gene Results in a Safe and Highly Immunogenic Candidate Live Attenuated Vaccine for Tuberculosis

Joseph Hinchey, Bo‐Young Jeon, Holly M. Alley, +7

PLoS ONE

Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer

Abigail B. McLeod, James P. Stice, Suzanne E. Wardell, +3

The Prostate

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Julie A. Pollock, Suzanne E. Wardell, A.A. Parent, +12

Nature Chemical Biology

UrologyMedicineHormonal ReceptorCastration-resistant Prostate CancerProstatic Disease +2